Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech buyouts.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(319)
•••
Comment by jimsenioron Oct 10, 2022 5:52pm
198 Views
Post# 35016152

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Biotech buyouts.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Biotech buyouts.Yes. Thank you. Royalty was the word I was looking for. I heard that somehow the MC royalty was dealt with; but who knows.

I have been looking at the AN agreement, and don't get it much more now than I did in 2017. I think we can say AN has not started a Phase 3 mBC, so there is that. I am thinking that matters have changed so much since the inception of that deal that AN may in fact not be pursuing it, and that that territory is available. Assuming someone is interested in ONCY that should represent considerable value. Yes , speculation on my part.

Apologies to bhenry for all the specualtion and questions, but I am trying to decide whether or not to add a few shares, and am seeking further clarity.

Cheers
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities